391 related articles for article (PubMed ID: 17413689)
21. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
Tam LW; Hogg RS; Yip B; Montaner JS; Harrigan PR; Brumme CJ
HIV Med; 2007 Jul; 8(5):267-70. PubMed ID: 17561871
[TBL] [Abstract][Full Text] [Related]
22. Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response.
Fardet L; Mary-Krause M; Heard I; Partisani M; Costagliola D;
HIV Med; 2006 Nov; 7(8):520-9. PubMed ID: 17105511
[TBL] [Abstract][Full Text] [Related]
23. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
Grover SA; Coupal L; Gilmore N; Mukherjee J
Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096
[TBL] [Abstract][Full Text] [Related]
24. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
[TBL] [Abstract][Full Text] [Related]
25. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
[TBL] [Abstract][Full Text] [Related]
26. Predictors of failure of first-line antiretroviral therapy in HIV-infected adults: Indian experience.
Rajasekaran S; Jeyaseelan L; Vijila S; Gomathi C; Raja K
AIDS; 2007 Jul; 21 Suppl 4():S47-53. PubMed ID: 17620752
[TBL] [Abstract][Full Text] [Related]
27. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH;
Clin Infect Dis; 2009 May; 48(10):1459-66. PubMed ID: 19348592
[TBL] [Abstract][Full Text] [Related]
28. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
[TBL] [Abstract][Full Text] [Related]
29. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users.
Ferreros I; Lumbreras B; Hurtado I; Pérez-Hoyos S; Hernández-Aguado I
Addiction; 2008 Apr; 103(4):651-9. PubMed ID: 18339110
[TBL] [Abstract][Full Text] [Related]
30. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era.
Chiao EY; Giordano TP; Richardson P; El-Serag HB
J Clin Oncol; 2008 Jan; 26(3):474-9. PubMed ID: 18202423
[TBL] [Abstract][Full Text] [Related]
31. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
[TBL] [Abstract][Full Text] [Related]
32. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.
Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
Antivir Ther; 2004 Apr; 9(2):229-35. PubMed ID: 15134185
[TBL] [Abstract][Full Text] [Related]
33. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of antiretroviral treatment in a South African program: a cohort study.
Fairall LR; Bachmann MO; Louwagie GM; van Vuuren C; Chikobvu P; Steyn D; Staniland GH; Timmerman V; Msimanga M; Seebregts CJ; Boulle A; Nhiwatiwa R; Bateman ED; Zwarenstein MF; Chapman RD
Arch Intern Med; 2008 Jan; 168(1):86-93. PubMed ID: 18195200
[TBL] [Abstract][Full Text] [Related]
35. Effect of education on overall and cause-specific mortality in injecting drug users, according to HIV and introduction of HAART.
Jarrin I; Lumbreras B; Ferreros I; Pérez-Hoyos S; Hurtado I; Hernández-Aguado I
Int J Epidemiol; 2007 Feb; 36(1):187-94. PubMed ID: 17085455
[TBL] [Abstract][Full Text] [Related]
36. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
38. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda.
Mills EJ; Bakanda C; Birungi J; Chan K; Ford N; Cooper CL; Nachega JB; Dybul M; Hogg RS
Ann Intern Med; 2011 Aug; 155(4):209-16. PubMed ID: 21768555
[TBL] [Abstract][Full Text] [Related]
39. Survival of HIV-infected patients after starting tuberculosis treatment: a prospective cohort study.
Maruza M; Albuquerque MF; Braga MC; Barbosa MT; Byington R; Coimbra I; Moura LV; Batista JD; Diniz GT; Miranda-Filho DB; Lacerda HR; Rodrigues LC; Ximenes RA
Int J Tuberc Lung Dis; 2012 May; 16(5):618-24. PubMed ID: 22410415
[TBL] [Abstract][Full Text] [Related]
40. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
Zoufaly A; Stellbrink HJ; Heiden MA; Kollan C; Hoffmann C; van Lunzen J; Hamouda O;
J Infect Dis; 2009 Jul; 200(1):79-87. PubMed ID: 19476437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]